# Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)

> **NCT04574583** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 12 (actual)

## Conditions studied

- Metastatic Cancer
- Solid Tumors

## Interventions

- **DRUG:** SX-682
- **DRUG:** M7824
- **BIOLOGICAL:** MVA-BN-CV301
- **BIOLOGICAL:** recombinant fowlpox viral (FPV)-CV301

## Key facts

- **NCT ID:** NCT04574583
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-24
- **Primary completion:** 2023-02-07
- **Final completion:** 2023-05-19
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04574583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04574583, "Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04574583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*